BOND Oracle HER2 IHC System
Leica Biosystems · Decision date Jun 4, 2026
What did the FDA decide?
FDA records P090015/S014 as a supplement to PMA P090015, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jun 4, 2026.
FDA approval order statement
a manufacturing QC change
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Pathology
- Decision date
- Jun 4, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P090015/S014
- Regulatory pathway
- PMA supplement
- Applicant
- Leica Biosystems
- Product code
- MVC
- Decision code
- OK30
- Decision date
- Jun 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: SYSTEM, TEST, HER-2/NEU, IHC.
- Applicant
- Leica Biosystems
- Product code
- MVC
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P090015/S014 received
Application receipt date recorded by FDA.
P090015/S014 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P090015. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code MVC
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
HercepTestP980018/S027 | Agilent Technologies Singapore (International) Pte , Ltd. | PMA supplement | Sep 21, 2026 | FDA |
| Ventana Medical Systems, Inc. | PMA supplement | Aug 25, 2026 | FDA | |
| Ventana Medical Systems, Inc. | PMA supplement | May 15, 2026 | FDA | |
HercepTestP980018/S026 | Agilent Technologies Singapore (International) Pte , Ltd. | PMA supplement | Jan 28, 2026 | FDA |
| Ventana Medical Systems, Inc. | PMA supplement | Dec 15, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Leica Biosystems
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 36 Cherry Hill Dr., Danvers, MA, 01923
Sources and methodology
- Original FDA record: P090015/S014
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



